NCT06494475View on ClinicalTrials.gov

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

564

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

June 21, 2025

Study Completion Date

June 21, 2025

Conditions
Streptococcus Agalactiae Infection
Interventions
DRUG

GBS-NN/NN2 vaccine

Intramuscular injection.

DRUG

Tdap vaccine

Intramuscular injection.

DRUG

Placebo

Intramuscular injection.

Sponsors

Lead Sponsor

Minervax ApS
All Listed Sponsors
lead

Minervax ApS

OTHER

NCT06494475 - GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age | Biotech Hunter | Biotech Hunter